76 related articles for article (PubMed ID: 2185688)
1. Schedule-dependent effectiveness of ADM and multiple cycles of DDP on a murine reticulum sarcoma.
Leonetti C; Zupi G; Calabresi F; Greco C
Anticancer Res; 1990; 10(1):45-8. PubMed ID: 2185688
[TBL] [Abstract][Full Text] [Related]
2. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
4. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
6. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
7. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
8. cis-Dichlorodiammineplatinum(II) and adriamycin treatment of advanced ovarian cancer.
Briscoe KE; Pasmantier MW; Ohnuma T; Kennedy BJ
Cancer Treat Rep; 1978 Dec; 62(12):2027-30. PubMed ID: 751711
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model.
Berek JS; Schink JC; Knox RM
Obstet Gynecol; 1989 Oct; 74(4):663-6. PubMed ID: 2797645
[TBL] [Abstract][Full Text] [Related]
10. Time-dependent influence of procaine hydrochloride on cisplatin antitumor activity in P388 tumor bearing mice.
Viale M; Vánnozzi MO; Mandys V; Esposito M
Anticancer Res; 2001; 21(1A):485-7. PubMed ID: 11299784
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer.
Naumann RW; Alvarez RD; Omura GA; Segars E; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Dec; 71(3):450-3. PubMed ID: 9887248
[TBL] [Abstract][Full Text] [Related]
12. [The effectiveness of platinum in mono- anc combination therapy in a prospective multicenter study].
Krafft W
Zentralbl Gynakol; 1989; 111(14):938-46. PubMed ID: 2678834
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
14. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
15. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
16. Influence of treatment sequence on efficacy of fluorouracil and cisplatin intratumoral drug delivery in vivo.
Yu NY; Patawaran MB; Chen JY; Orenberg EK; Brown DM; Luck EE
Cancer J Sci Am; 1995; 1(3):215-21. PubMed ID: 9166479
[TBL] [Abstract][Full Text] [Related]
17. Optimum time sequence for the administration of cyclophosphamide and other drugs in vivo.
Mattern J; Wauss K; Volm M
Anticancer Res; 1985; 5(2):173-8. PubMed ID: 4039550
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 1 alpha (IL-1) and macrophage colony-stimulating factor (M-CSF) accelerate recovery from multiple drug-induced myelosuppression.
Kovacs CJ; Kerr JA; Daly BM; Evans MJ; Johnke RM
Anticancer Res; 1998; 18(3A):1805-12. PubMed ID: 9673408
[TBL] [Abstract][Full Text] [Related]
19. High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma.
O'Connell G; Shelley W; Carmichael J; Fraser R; Kirk ME; Krepart G; Levin L; Swenerton K
Cancer Treat Rep; 1987 May; 71(5):455-8. PubMed ID: 3567969
[TBL] [Abstract][Full Text] [Related]
20. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
Damia G; Tagliabue G; Zucchetti M; Davoli E; Sessa C; Cavalli F; D'Incalci M
Cancer Chemother Pharmacol; 1992; 30(6):459-64. PubMed ID: 1394802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
